Aberdeen Group plc Invests $4.56 Million in Sera Prognostics, Inc. $SERA

Key Points

• Aberdeen Group plc has invested approximately $4.56 million in Sera Prognostics, acquiring 1,240,000 shares, which represents 3.29% of the company.
• CEO Zhenya Lindgardt sold 23,042 shares at an average price of $1.43, resulting in a decrease in their ownership by 2.66% and leaving them with 844,209 shares valued at about $1.2 million.
• Sera Prognostics reported a quarterly EPS of ($0.16), which exceeded the consensus estimate of ($0.21), but the company still faces a negative net margin of 30,306.48%.

Aberdeen Group plc acquired a new stake in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 1,240,000 shares of the company's stock, valued at approximately $4,563,000. Aberdeen Group plc owned 3.29% of Sera Prognostics as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Sera Prognostics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 599,702 shares of the company's stock valued at $4,883,000 after buying an additional 12,865 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Sera Prognostics by 55.2% during the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company's stock worth $107,000 after acquiring an additional 4,691 shares during the period. Townsquare Capital LLC bought a new stake in Sera Prognostics in the 4th quarter valued at $130,000. Barclays PLC boosted its stake in Sera Prognostics by 13.4% in the 4th quarter. Barclays PLC now owns 44,722 shares of the company's stock worth $364,000 after purchasing an additional 5,272 shares during the period. Finally, Walleye Capital LLC bought a new position in Sera Prognostics during the 4th quarter worth about $98,000. 54.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 23,042 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.43, for a total value of $32,950.06. Following the completion of the transaction, the chief executive officer directly owned 844,209 shares in the company, valued at $1,207,218.87. This trade represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 44,014 shares of company stock worth $68,588 over the last ninety days. Corporate insiders own 13.50% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th.

Sera Prognostics Stock Performance

Sera Prognostics stock opened at $2.25 on Thursday. Sera Prognostics, Inc. has a 1-year low of $1.37 and a 1-year high of $9.13. The company has a fifty day simple moving average of $2.52 and a 200 day simple moving average of $3.02. The company has a market cap of $84.76 million, a P/E ratio of -2.65 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. On average, equities research analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

Want to see what other hedge funds are holding SERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sera Prognostics, Inc. (NASDAQ:SERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.